Avidity Biosciences Profit Margin

Avidity Biosciences (RNA) currently reports a profit margin of -1246.35% as of June 2026. That compares with -4247.77% in the prior-year period — up 70.7% year over year. That is below the Healthcare sector average of 13.76%. Use the charts on this page to explore Avidity Biosciences's profit margin history and peer comparisons.

Avidity Biosciences's profit margin increased from -4247.77% to -1246.35% — a 70.7% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Avidity Biosciences's profit margin of -1246.35% is lower than the Healthcare sector average of 13.76%. That is roughly 9157.6% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Avidity Biosciences's current -1246.35% should be judged against Healthcare norms (sector average: 13.76%) and against RNA's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -1246.35%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.76%. From there, open related valuation or income-statement pages for Avidity Biosciences, and consider following RNA for alerts when major investors trade the stock.